HQL
Tekla Life Sciences InvestorsNYSEFinancial Services$16.84-0.06%OpenMarket Cap: $486.2M
As of 2026-04-06
Valuation
P/E (TTM)
2.85
PEG
0.01
P/B
0.95
P/S
16.30
EV/EBITDA
5.68
DCF Value
$91.97
FCF Yield
-0.5%
Div Yield
11.3%
Margins & Returns
Gross Margin
30.8%
Operating Margin
286.9%
Net Margin
286.9%
ROE
18.8%
ROA
16.6%
ROIC
16.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $11.6M | 79.0% | $132.8M | $132.8M | $4.60 | $0.42 |
| FY 2025 | $86.4M | 100.0% | $85.6M | $85.6M | $2.96 | $1.82 |
| Q2 2025 | $18.2M | 0.0% | $-47.2M | $-47.2M | $-1.64 | $0.47 |
| Q4 2024 | $1.9M | 100.0% | $-1.3M | $35.0M | $1.22 | $0.49 |
| FY 2024 | $86.7M | 100.0% | $85.3M | $85.3M | $3.04 | $1.66 |
| Q2 2024 | $2.1M | 100.0% | $-653.3K | $50.3M | $1.84 | $0.39 |
| Q4 2023 | $29.6M | 91.2% | $-11.4M | $-11.5M | $-0.43 | $0.32 |
| FY 2023 | $39.4M | 46.4% | $-5.2M | $22.4M | $0.79 | $1.28 |
| Q2 2023 | $1.9M | 100.0% | $-940.7K | $33.8M | $1.29 | $0.33 |
| Q4 2022 | $21.7M | 87.8% | $-28.3M | $-28.3M | $-1.10 | $0.31 |
| FY 2022 | $31.9M | 82.6% | $-104.6M | $-104.6M | $-4.07 | $1.47 |
| Q2 2022 | $10.2M | 71.4% | $-76.3M | $-76.3M | $-3.03 | $0.39 |